Pasithea Therapeutics Corp. (KTTA)
US — Healthcare Sector
Automate Your Wheel Strategy on KTTA
With Tiblio's Option Bot, you can configure your own wheel strategy including KTTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KTTA
- Rev/Share 0.0
- Book/Share 5869.5468
- PB 0.0001
- Debt/Equity 0.0
- CurrentRatio 3.8403
- ROIC -0.0011
- MktCap 5765795.0
- FreeCF/Share -1386.2833
- PFCF -0.0019
- PE -0.1259
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0042
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
KTTA
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients
Read More
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
KTTA
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Pasithea Therapeutics (Nasdaq: KTTA) prices $5M public offering to fund clinical trials, R&D, and corporate initiatives; closing expected May 7, 2025.
Read More
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
KTTA
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.
Read More
About Pasithea Therapeutics Corp. (KTTA)
- IPO Date 2021-09-15
- Website https://www.pasithea.com
- Industry Biotechnology
- CEO Dr. Tiago Reis Marques M.D., Ph.D.
- Employees 4
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.